Nuvalent Shares Surge 39% as GSK Strikes $10.6 Billion Cancer Drug Deal
Nuvalent shares surged nearly 39% in premarket trading after British pharmaceutical giant GSK agreed to buy the U.S. cancer drugmaker for $10.6 billion, a major bet on lung cancer treatments…







